Skip to main content
Erschienen in: Neurological Sciences 3/2022

17.08.2021 | Original Article

Ten years evaluation of epidemiology- and mortality-related factors in adults and children with Guillain-Barré syndrome in the north of Iran

verfasst von: Mozaffar Hosseininezhad, Seyed Sepehr Khatami, Sajjad Saadat, Mona Asghari, Hoora Ghovvati Choshal, Alireza Hooshmand Marvasti, Zahra Gholipour Soleimani

Erschienen in: Neurological Sciences | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

Guillain-Barré syndrome (GBS) is the main cause of acute and subacute flaccid paralysis in western nations since the eradication of poliomyelitis.

Objective

The aim of this study is to investigate epidemiology and mortality characteristics of GBS in the north of Iran.

Material and methods

In this study, the hospital information system (HIS) was used to access each patient’s information. The final 174 cases were examined in terms of age, sex, place of residence, the year of referral, the month of referral, the season of referral, client city, accompanying background disease, and the type of GBS.

Results

The mean incidence rate in Guilan province was about 0.69 in 100,000 persons, and the case fatality rate was 10.34%. The most reported type of GBS was AIDP (33.90%), and the most common symptom was upper and lower limbs paresis in 65 cases (37%). Respiratory distress (P =  < 0.001), complications during hospitalization (P = 0.0001), and ICU requirement (P = 0.001) were significantly higher in dead patients.

Conclusion

In this study, the incidence of GBS was higher in men than women and the highest number of cases was in the age group of 60 to 75 years. The significant point was the high-case fatality rate in Guilan province compared to the previous studies. The complications during hospitalization such as respiratory distress, ICU requirement, and underlying disease had a significant relation with the fatality of GBS.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Pithadia AB, Kakadia N (2010) Guillain-Barré syndrome (GBS). Pharmacol Rep 62(2):220–232CrossRef Pithadia AB, Kakadia N (2010) Guillain-Barré syndrome (GBS). Pharmacol Rep 62(2):220–232CrossRef
2.
Zurück zum Zitat Sipilä JO et al (2017) Epidemiology of Guillain-Barré syndrome in Finland 2004–2014. J Peripher Nerv Syst 22(4):440–445CrossRef Sipilä JO et al (2017) Epidemiology of Guillain-Barré syndrome in Finland 2004–2014. J Peripher Nerv Syst 22(4):440–445CrossRef
3.
Zurück zum Zitat El-Beleidy AS et al (2013) Antiganglioside antibodies determine the clinical severity and predict response to therapy in Egyptian children with Guillain-Barré Syndrome. Pediatr Pol 88(3):224–229CrossRef El-Beleidy AS et al (2013) Antiganglioside antibodies determine the clinical severity and predict response to therapy in Egyptian children with Guillain-Barré Syndrome. Pediatr Pol 88(3):224–229CrossRef
4.
Zurück zum Zitat Jacobs BC et al (2017) International Guillain-Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome. J Peripher Nerv Syst 22(2):68–76CrossRef Jacobs BC et al (2017) International Guillain-Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome. J Peripher Nerv Syst 22(2):68–76CrossRef
5.
Zurück zum Zitat Benedetti MD et al (2015) A multicentric prospective incidence study of Guillain-Barré syndrome in Italy. the ITANG study. Neuroepidemiology 45(2):90–99CrossRef Benedetti MD et al (2015) A multicentric prospective incidence study of Guillain-Barré syndrome in Italy. the ITANG study. Neuroepidemiology 45(2):90–99CrossRef
6.
Zurück zum Zitat Momen AA, Shakurnia A (2017) The epidemiology of guillain-barré syndrome in children under 15 years old in Southwest Iran. Biomed Hub 2(3):1–8CrossRef Momen AA, Shakurnia A (2017) The epidemiology of guillain-barré syndrome in children under 15 years old in Southwest Iran. Biomed Hub 2(3):1–8CrossRef
7.
Zurück zum Zitat Kwong JC et al (2013) Risk of Guillain-Barré syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study. Lancet Infect Dis 13(9):769–776CrossRef Kwong JC et al (2013) Risk of Guillain-Barré syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study. Lancet Infect Dis 13(9):769–776CrossRef
8.
Zurück zum Zitat Wachira VK, Peixoto HM, de Oliveira MRF (2019) Systematic review of factors associated with the development of Guillain-Barré syndrome 2007–2017: what has changed? Tropical Med Int Health 24(2):132–142CrossRef Wachira VK, Peixoto HM, de Oliveira MRF (2019) Systematic review of factors associated with the development of Guillain-Barré syndrome 2007–2017: what has changed? Tropical Med Int Health 24(2):132–142CrossRef
9.
Zurück zum Zitat Ogawara K et al (2000) Axonal Guillain-Barré syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann Neurol 48(4):624–631CrossRef Ogawara K et al (2000) Axonal Guillain-Barré syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann Neurol 48(4):624–631CrossRef
10.
Zurück zum Zitat Kobori S et al (2017) Coexisting infectious diseases on admission as a risk factor for mechanical ventilation in patients with Guillain-Barré syndrome. J Epidemiol 27(7):311–316CrossRef Kobori S et al (2017) Coexisting infectious diseases on admission as a risk factor for mechanical ventilation in patients with Guillain-Barré syndrome. J Epidemiol 27(7):311–316CrossRef
11.
Zurück zum Zitat Parra B et al (2016) Guillain-Barré syndrome associated with Zika virus infection in Colombia. N Engl J Med 375(16):1513–1523CrossRef Parra B et al (2016) Guillain-Barré syndrome associated with Zika virus infection in Colombia. N Engl J Med 375(16):1513–1523CrossRef
12.
Zurück zum Zitat Grave C et al (2020) Seasonal influenza vaccine and Guillain-Barré syndrome: a self-controlled case series study. Neurology 94(20):e2168–e2179CrossRef Grave C et al (2020) Seasonal influenza vaccine and Guillain-Barré syndrome: a self-controlled case series study. Neurology 94(20):e2168–e2179CrossRef
13.
Zurück zum Zitat Racca F et al (2020) Practical approach to respiratory emergencies in neurological diseases. Neurol Sci 41(3):497–508CrossRef Racca F et al (2020) Practical approach to respiratory emergencies in neurological diseases. Neurol Sci 41(3):497–508CrossRef
14.
Zurück zum Zitat Wijdicks EF, Klein CJ (2017) Guillain-barré syndrome. In Mayo clinic proceedings, vol 92, No. 3. Elsevier, pp 467–479 Wijdicks EF, Klein CJ (2017) Guillain-barré syndrome. In Mayo clinic proceedings, vol 92,  No. 3. Elsevier, pp 467–479
16.
Zurück zum Zitat Li C et al (2020) The effects of IVIg therapy on serum levels of neuropeptide Y and cytokines in Guillain-Barré syndrome. Neurol Sci 41(2):295–303CrossRef Li C et al (2020) The effects of IVIg therapy on serum levels of neuropeptide Y and cytokines in Guillain-Barré syndrome. Neurol Sci 41(2):295–303CrossRef
17.
Zurück zum Zitat Arami MA, Yazdchi M, Khandaghi R (2006) Epidemiology and characteristics of Guillain-Barre syndrome in the northwest of Iran. Ann Saudi Med 26(1):22–27CrossRef Arami MA, Yazdchi M, Khandaghi R (2006) Epidemiology and characteristics of Guillain-Barre syndrome in the northwest of Iran. Ann Saudi Med 26(1):22–27CrossRef
18.
Zurück zum Zitat Yadegari S, Kazemi N, Nafissi S (2014) Clinical and electrophysiological features of Guillain-Barré syndrome in Iran. J Clin Neurosci 21(9):1554–1557CrossRef Yadegari S, Kazemi N, Nafissi S (2014) Clinical and electrophysiological features of Guillain-Barré syndrome in Iran. J Clin Neurosci 21(9):1554–1557CrossRef
19.
Zurück zum Zitat Alshekhlee A et al (2008) Guillain-Barré syndrome: incidence and mortality rates in US hospitals. Neurology 70(18):1608–1613CrossRef Alshekhlee A et al (2008) Guillain-Barré syndrome: incidence and mortality rates in US hospitals. Neurology 70(18):1608–1613CrossRef
20.
Zurück zum Zitat Yakoob MY et al (2005) Characteristics of patients with Guillain Barre Syndrome at a tertiary care centre in Pakistan, 1995–2003. J Pak Med Assoc 55(11):493PubMed Yakoob MY et al (2005) Characteristics of patients with Guillain Barre Syndrome at a tertiary care centre in Pakistan, 1995–2003. J Pak Med Assoc 55(11):493PubMed
21.
Zurück zum Zitat Said SD (2009) Clinical experience with Gullain Barre syndrome over a 6-year period in one hospital in the Middle East. Jordan Med J 43(4):280–285 Said SD (2009) Clinical experience with Gullain Barre syndrome over a 6-year period in one hospital in the Middle East. Jordan Med J 43(4):280–285
22.
Zurück zum Zitat Radhakrishnan K, El-Mangoush M, Gerryo S (1987) Descriptive epidemiology of selected neuromuscular disorders in Benghazi, Libya. Acta Neurol Scand 75(2):95–100CrossRef Radhakrishnan K, El-Mangoush M, Gerryo S (1987) Descriptive epidemiology of selected neuromuscular disorders in Benghazi, Libya. Acta Neurol Scand 75(2):95–100CrossRef
23.
Zurück zum Zitat Bölükbaşi F et al (2019) Guillain-barré syndrome and its variants: Clinical course and prognostic factors. Arch Neuropsychiatry 56(1):71 Bölükbaşi F et al (2019) Guillain-barré syndrome and its variants: Clinical course and prognostic factors. Arch Neuropsychiatry 56(1):71
24.
Zurück zum Zitat Benamer HT, Bredan A (2014) Guillain-Barré syndrome in Arab countries: a systematic review. J Neurol Sci 343(1–2):221–223CrossRef Benamer HT, Bredan A (2014) Guillain-Barré syndrome in Arab countries: a systematic review. J Neurol Sci 343(1–2):221–223CrossRef
25.
Zurück zum Zitat Granieri E et al (2019) Incidence study of Guillain-Barré syndrome in the province of Ferrara, Northern Italy, between 2003 and 2017. A 40-year follow-up. Neurol Sci 40(3):603–609CrossRef Granieri E et al (2019) Incidence study of Guillain-Barré syndrome in the province of Ferrara, Northern Italy, between 2003 and 2017. A 40-year follow-up. Neurol Sci 40(3):603–609CrossRef
26.
Zurück zum Zitat Al-Hakem H et al (2019) Guillain-Barré syndrome in Denmark: a population-based study on epidemiology, diagnosis and clinical severity. J Neurol 266(2):440–449CrossRef Al-Hakem H et al (2019) Guillain-Barré syndrome in Denmark: a population-based study on epidemiology, diagnosis and clinical severity. J Neurol 266(2):440–449CrossRef
27.
Zurück zum Zitat van Doorn PA (2013) Diagnosis, treatment and prognosis of Guillain-Barré syndrome (GBS). La Presse Médicale 42(6 Part 2):e193–e201CrossRef van Doorn PA (2013) Diagnosis, treatment and prognosis of Guillain-Barré syndrome (GBS). La Presse Médicale 42(6 Part 2):e193–e201CrossRef
28.
Zurück zum Zitat Pritchard J (2010) Guillain-Barré syndrome. Clin Med (Lond) 10(4):399–401CrossRef Pritchard J (2010) Guillain-Barré syndrome. Clin Med (Lond) 10(4):399–401CrossRef
29.
Zurück zum Zitat Incecik F, Hergüner MO, Altunbasak S (2011) Guillain-Barré syndrome in children. Neurol Sci 32(3):381–385CrossRef Incecik F, Hergüner MO, Altunbasak S (2011) Guillain-Barré syndrome in children. Neurol Sci 32(3):381–385CrossRef
30.
Zurück zum Zitat Lin J-J et al (2012) Clinical variants of Guillain-Barré syndrome in children. Pediatr Neurol 47(2):91–96CrossRef Lin J-J et al (2012) Clinical variants of Guillain-Barré syndrome in children. Pediatr Neurol 47(2):91–96CrossRef
31.
32.
Zurück zum Zitat Wang Y et al (2016) Complications of Guillain-Barré syndrome. Expert Rev Clin Immunol 12(4):439–448CrossRef Wang Y et al (2016) Complications of Guillain-Barré syndrome. Expert Rev Clin Immunol 12(4):439–448CrossRef
33.
Zurück zum Zitat Kim J-E et al (2017) Neurological complications during treatment of Middle East respiratory syndrome. J Clin Neurol (Seoul, Korea) 13(3):227CrossRef Kim J-E et al (2017) Neurological complications during treatment of Middle East respiratory syndrome. J Clin Neurol (Seoul, Korea) 13(3):227CrossRef
34.
Zurück zum Zitat Rahimi K (2020) Guillain-Barre syndrome during COVID-19 pandemic: an overview of the reports. Neurol Sci 41(11):3149–3156CrossRef Rahimi K (2020) Guillain-Barre syndrome during COVID-19 pandemic: an overview of the reports. Neurol Sci 41(11):3149–3156CrossRef
35.
Zurück zum Zitat Abu-Rumeileh S, Abdelhak A, Foschi M, Tumani H, Otto M (2021) Guillain–Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. J Neurol 268(4):1133–1170 Abu-Rumeileh S, Abdelhak A, Foschi M, Tumani H, Otto M (2021) Guillain–Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. J Neurol 268(4):1133–1170
36.
Zurück zum Zitat Alberti P, Beretta S, Piatti M, Karantzoulis A, Piatti ML, Santoro P, Ferrarese C (2020) Guillain-Barré syndrome related to COVID-19 infection. Neurol-Neuroimmunol Neuroinflam 7(4) Alberti P, Beretta S, Piatti M, Karantzoulis A, Piatti ML, Santoro P, Ferrarese C (2020) Guillain-Barré syndrome related to COVID-19 infection. Neurol-Neuroimmunol Neuroinflam 7(4)
37.
Zurück zum Zitat Caress JB et al (2020) COVID-19–associated Guillain-Barré syndrome: the early pandemic experience. Muscle Nerve 62(4):485–491CrossRef Caress JB et al (2020) COVID-19–associated Guillain-Barré syndrome: the early pandemic experience. Muscle Nerve 62(4):485–491CrossRef
38.
Zurück zum Zitat Sedaghat Z, Karimi N (2020) Guillain Barre syndrome associated with COVID-19 infection: a case report. J Clin Neurosci 76:233–235CrossRef Sedaghat Z, Karimi N (2020) Guillain Barre syndrome associated with COVID-19 infection: a case report. J Clin Neurosci 76:233–235CrossRef
39.
Zurück zum Zitat Uncini A, Vallat J-M, Jacobs BC (2020) Guillain-Barré syndrome in SARS-CoV-2 infection: an instant systematic review of the first six months of pandemic. J Neurol Neurosurg Psychiatry 91(10):1105–1110CrossRef Uncini A, Vallat J-M, Jacobs BC (2020) Guillain-Barré syndrome in SARS-CoV-2 infection: an instant systematic review of the first six months of pandemic. J Neurol Neurosurg Psychiatry 91(10):1105–1110CrossRef
40.
Zurück zum Zitat Haber P et al (2004) Guillain-Barré syndrome following influenza vaccination. JAMA 292(20):2478–2481CrossRef Haber P et al (2004) Guillain-Barré syndrome following influenza vaccination. JAMA 292(20):2478–2481CrossRef
41.
Zurück zum Zitat Polack FP et al (2020) Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 383(27):2603–2615CrossRef Polack FP et al (2020) Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 383(27):2603–2615CrossRef
42.
Zurück zum Zitat Oliver SE (2020) The advisory committee on immunization practices’ interim recommendation for use of moderna COVID-19 vaccine—United States, December 2020. MMWR. Morbid Mortal Week Rep 69 Oliver SE (2020) The advisory committee on immunization practices’ interim recommendation for use of moderna COVID-19 vaccine—United States, December 2020. MMWR. Morbid Mortal Week Rep 69
Metadaten
Titel
Ten years evaluation of epidemiology- and mortality-related factors in adults and children with Guillain-Barré syndrome in the north of Iran
verfasst von
Mozaffar Hosseininezhad
Seyed Sepehr Khatami
Sajjad Saadat
Mona Asghari
Hoora Ghovvati Choshal
Alireza Hooshmand Marvasti
Zahra Gholipour Soleimani
Publikationsdatum
17.08.2021
Verlag
Springer International Publishing
Erschienen in
Neurological Sciences / Ausgabe 3/2022
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-021-05562-y

Weitere Artikel der Ausgabe 3/2022

Neurological Sciences 3/2022 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.